Kier M.G.G., Lauritsen J., Almstrup K., Mortensen M.S., Toft B.G., Rajpert-De Meyts E., Skakkebaek N.E., Rørth M., Von Der Maase H., Agerbaek M., Holm N.V., Andersen K.K., Dalton S.O., Johansen C., Daugaard G.
Annals of Oncology 2015 26:4 (737-742)
Background: Screening programmes for contralateral carcinoma in situ (CIS) testis in patients with unilateral germ-cell cancer (GCC) have never been evaluated. We investigated the effect of screening for contralateral CIS in a large nationwide, population-based study. Patients and methods: A contralateral single-site biopsy was offered to 4130 patients in whom GCC had been diagnosed in 1984-2007 (screened cohort); 462 patients in whom GCC was diagnosed in 1984-1988 comprised the unscreened cohort. Cases with CIS were offered radiotherapy. Initially CIS-negative biopsies in patients with metachronous GCC were revised according to today’s standards. Risk for metachronous GCC was estimated using cumulative incidence and the Cox proportional hazards model. Results: In the screened cohort, contralateral CIS was found in 181 (4.4%) patients. The cumulative incidence of metachronous GCC after 20 years was 1.9% in the screened cohort and…(vermás)